Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Insulin efsitora alfa is a long-acting insulin analog fused to a human IgG2 Fc region, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Mechanism
- Curator reviewed · 4 references
Insulin efsitora alfa regulates glucose metabolism; insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis and enhances protein synthesis. The protracted time-action profile of insulin efsitora alfa results from reduced renal clearance due to its relatively large molecular size, inhibition of degradation due to binding at the neonatal Fc receptor, and reduced affinity relative to human insulin for the insulin receptor, which decreases receptor-mediated clearance. Once engaged with the insulin receptor, insulin efsitora alfa produces the same pharmacological effects as human insulin.
- Primary indication
- Insulin efsitora alfa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 1 structured indication
- First approval
- United States, 2026
- Also known as
- Insulin efsitora
- Code names
- LY-3209590
Resolves to
What you can answer from here — as of October 28, 2026
Which drugs share a target with Insulin efsitora alfa, and which of those have an active Phase 3 trial?